Sandoz Group AG (Sandoz Group AG) Accounts Payable & Accrued Expense : $2,430 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Accounts Payable & Accrued Expense?

Sandoz Group AG's quarterly accounts payable & accrued expense increased from . 20 ($0 Mil) to Dec. 2022 ($1,789 Mil) and increased from Dec. 2022 ($1,789 Mil) to Dec. 2023 ($2,430 Mil).

Sandoz Group AG's annual accounts payable & accrued expense increased from . 20 ($0 Mil) to Dec. 2022 ($1,789 Mil) and increased from Dec. 2022 ($1,789 Mil) to Dec. 2023 ($2,430 Mil).

Sandoz Group AG Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sandoz Group AG's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Accounts Payable & Accrued Expense Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Accounts Payable & Accrued Expense

1,789.00

2,430.00

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Accounts Payable & Accrued Expense	1,789.00	2,430.00

Sandoz Group AG Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024